C
Century Therapeutics, Inc. (IPSC)
NCM – Real Time Price. Currency in USD
2.32
+0.02 (0.87%)
At close: Jun 26, 2026, 4:00 PM EDT
2.36
+0.04 (1.72%)
After-hours: Jun 26, 2026, 6:51 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.32
+0.02 (0.87%)
At close: Jun 26, 2026, 4:00 PM EDT
2.36
+0.04 (1.72%)
After-hours: Jun 26, 2026, 6:51 PM EDT
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Brent Pfeiffenberger M.B.A., Pharm.D. | President, CEO & Chairman |
| Dr. Chad A. Cowan Ph.D. | Chief Scientific Officer |
| Dr. Gregory Russotti Ph.D. | Chief Technology & Manufacturing Officer |
| Krista Kauppinen J.D., Ph.D. | VP, General Counsel & Head of Intellectual Property |
| Michael Naso Ph.D. | Senior VP of Cell Engineering |
| Mr. Douglas Carr CPA | Senior VP of Finance & Operations, Principal Financial Officer and Secretary |
| Ms. Elizabeth Devlin | VP & Head of Development |
| Ms. Megan Bilson | Chief People Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-16 | 8-K | tm2617925d1_8k.htm |
| 2026-06-12 | 8-K | tm2617728d1_8k.htm |
| 2026-06-08 | 8-K | tm2617028d1_8k.htm |
| 2026-05-13 | 8-K | tm2614312d1_8k.htm |
| 2026-05-13 | 10-Q | ipsc-20260331x10q.htm |
| 2026-04-27 | DEF 14A | tm261507-6_def14a.htm |
| 2026-04-16 | PRE 14A | tm261507-4_pre14a.htm |
| 2026-04-16 | ARS | tm265719d2_ars.pdf |
| 2026-03-26 | 8-K | tm269823d1_8k.htm |
| 2026-03-12 | S-8 | tm268497d1_s8.htm |